Immune Regulation News 11.39 October 18, 2019 | |
| |
TOP STORYMechanosensing by Peyer’s Patch Stroma Regulates Lymphocyte Migration and Mucosal Antibody Responses Peyer’s patch fibroblastic reticular cells (FRCs) responded to conduit fluid flow via the mechanosensitive ion channel Piezo1. Disruption of fluid flow or genetic deficiency of Piezo1 on CCL19-expressing stroma led to profound structural alterations in perivascular FRCs and associated high endothelial venules. [Nat Immunol] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Computational analysis revealed broad shifts in both cell-type composition and cell programs in response to the inflammation, especially in group 2 innate lymphoid cells. [Immunity] Abstract | Graphical Abstract T Cells Redirected against Igβ for the Immunotherapy of B Cell Lymphoma The authors engineered T cells to express anti-Igβ CAR with CD28 costimulatory signaling moiety and observed that Igβ-CAR T cells could efficiently recognize and eliminate Igβ+ lymphoma cells both in vitro and in two different lymphoma xenograft models. [Leukemia] Abstract Researchers measured the expression of PD-L1 in multiple immune cells with two platforms and confocal microscopy on three retrospective Yale NSCLC cohorts. The PD-L1 level was selectively measured in different immune cell subsets using two multiplexed QIF panels including CD56 for natural killer cells, CD68 for macrophages and CD8 for cytotoxic T cells. [Clin Cancer Res] Abstract Investigators established regulatory phenotypes of sequential early T cell precursor (ETP) subsets, confirmed initial co-expression of progenitor with T cell specification genes, defined stage-specific relationships between cell cycle and differentiation, and generated a pseudotime model from ETP to T lineage commitment, supported by RNA velocity and transcription factor perturbations. [Cell Syst] Abstract | Graphical Abstract TET2 Regulates the Neuroinflammatory Response in Microglia Scientists showed that Ten-eleven translocation 2 (TET2) methylcytosine dioxygenase expression was increased in microglia upon stimulation with various inflammogens through a NF-κB-dependent pathway. [Cell Rep] Full Article | Graphical Abstract Researchers found that breast cancer cells upregulate the expression of immune checkpoints including PD-1, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and lymphocyte activation gene-3 (LAG-3) in CD4+ T cell subsets. [Vaccines] Abstract | Download Full Article The authors examined the expression of the interleukin (IL)-6 family cytokines in response to pharmacologically-induced endoplasmic reticulum (ER) stress in astrocytes and macrophages, which expressed IL-6 in response to ER stress through different mechanisms. [Sci Rep] Full Article Investigators found that coxsackievirus B5 infection induced CCL17 production and controlled the migration of CCR4+ DCs and CCR4+ Tregs to the pancreatic lymph nodes. [Sci Rep] Full Article In splenic CD4+ T cells isolated from hyperhomocysteinemia (HHcy)-ApoE−/− mice, shikonin treatment significantly inhibited HHcy-stimulated pyruvate kinase muscle isozyme 2 activity, interferon-γ secretion and the capacity of these T cells to promote macrophage proinflammatory polarization. [Acta Pharmacol Sin] Abstract Subscribe to our sister publications: Human Immunology News & Immunology of Infectious Disease News. | |
| |
REVIEWSThe authors discuss recent insights into the generation, homing, retention, and survival of tissue resident memory T (TRM) cells and share our perspectives on the biological characteristics of TRM cells in the recurrence of inflammatory skin disorders. [Cell Mol Immunol] Abstract Pathological Alteration and Therapeutic Implications of Sepsis-Induced Immune Cell Apoptosis Scientists focus on describing the major apoptosis process of immune cells with respect to physiologic and molecular mechanisms. Further, advances in apoptosis-targeted treatment modalities for sepsis are also discussed. [Cell Death Dis] Full Article Visit our reviews page to see a complete list of reviews in the immune regulation research field. | |
| |
INDUSTRY NEWSImaginAb, Inc. announced the signing of a multi-party collaboration agreement with AstraZeneca, Pfizer Inc. and Takeda Pharmaceutical Company Limited focused on furthering the clinical development of ImaginAb’s CD8 ImmunoPET technology. [ImaginAb, Inc.] Press Release Incyte Corporation announced positive results from the Novartis-sponsored pivotal Phase III REACH2 study evaluating ruxolitinib in patients with steroid-refractory acute graft-versus-host disease. [Incyte Corporation] Press Release Aurinia Pharmaceuticals Inc. reported that the last patient study visit has occurred in the AURORA Phase III lupus nephritis study. [Aurinia Pharmaceuticals Inc.] Press Release Principia Biopharma Inc. announced positive preliminary data from an ongoing Phase I/II trial of its investigational treatment, PRN1008, in a highly treatment-resistant and refractory patient population with immune thrombocytopenia. [Principia Biopharma Inc.] Press Release Nektar Therapeutics announced the initiation of a first-in-human, Phase I clinical study evaluating NKTR-255, an interleukin-15 (IL-15) receptor agonist, as monotherapy for patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma. [Nektar Therapeutics] Press Release AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for RINVOQ™, a once-daily selective and reversible JAK inhibitor, for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. [AbbVie] Press Release Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of two regimens of KEYTRUDA, Merck’s anti-PD-1 therapy, for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma. [Merck & Co., Inc.] Press Release I-Mab Biopharma and MorphoSys AG announced that I-Mab has received Investigational New Drug (IND) clearances from the National Medical Products Administration of China to expand the ongoing phase II and III clinical trials of TJ202/MOR202, MorphoSys’s human monoclonal anti-CD38 antibody for the treatment of multiple myeloma, also to mainland China. [I-Mab Biopharma] Press Release Nplate® (Romiplostim) Now Approved for Earlier Use in Adults with Immune Thrombocytopenia Amgen announced that the FDA approved Amgen’s Supplemental Biologics License Application for Nplate® to include new data in its US prescribing information showing sustained platelet responses in adults with immune thrombocytopenia, a rare, serious autoimmune disease characterized by low platelet counts. [Amgen] Press Release GammaDelta Therapeutics announced the formation of a spin-out company: Adaptate Biotherapeutics. While GammaDelta Therapeutics’ primary goal is to develop γδ T-cell based cell therapy products, the new spin-out will build on GammaDelta’s knowledge to modulate γδ T-cell activity using therapeutic antibodies, with the potential to trigger an immune response against cancer. [GammaDelta Therapeutics] Press Release | |
| |
POLICY NEWSBrexit Hits UK Science Funding and Workforce The first figures have emerged demonstrating that Brexit uncertainty has adversely affected UK research. They show Britain’s annual share of EU research funding has fallen by nearly a third since 2015. [The BBC] Editorial Scientific Integrity Bill Advances in US House with Bipartisan Support Despite their failure to attract a single Republican co-sponsor, Democrats in Congress have long insisted that a bill to strengthen scientific integrity across US government agencies takes a bipartisan stance and is not a veiled attack on the Trump administration’s attitude toward science. That claim of bipartisanship took a big step forward as the science committee of the US House of Representatives tweaked the bill to satisfy key Republicans on the panel. [ScienceInsider] Editorial
| |
EVENTSNEW 12th European Lupus Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESScientist – Human Immunology (STEMCELL Technologies Inc.) Postdoctoral Fellow – Immunology and Vaccines (University of Maryland) Chief – Laboratory of Allergic Diseases (National Institute of Allergy and Infectious Diseases) Postdoctoral Fellow – Cancer Immunology (University of Alabama at Birmingham) Postdoctoral Position – Interface of Stem Cell Biology and Immunology (Columbia University) Faculty Position – Tumor Immunology (University of Utah) Assistant Professor and Postdoctoral Fellows – Immunology (Chinese Academy of Sciences) Assistant Professor – Neuro-Immune/Neuro-Pharmacological Interactions (University of Pennsylvania) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Immune Regulation News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|